

How to submit prior authorization requests for medical benefit drugs

For Blue Cross commercial and BCN commercial

Revised May 2025

Follow these steps to submit prior authorization requests when prescribing most drugs covered under the medical benefit for Blue Cross Blue Shield of Michigan and Blue Care Network commercial members.

Note: The information below doesn't apply to oncology medical benefit drugs.

Michigan prescribers

To submit prior authorization requests electronically:

1. Log in to our provider portal (availability.com*).
2. Click *Payer Spaces* on the menu bar and click the BCBSM and BCN logo.
3. Click the *Medical/Pharm Drug Benefit Prior Auth (Commercial)* tile on the Applications tab.
4. In the Medical and Pharmacy Drug PA Portal, click the *Authorization* menu and select *Add New*.
5. Enter the member's last name, date of birth, subscriber ID and authorization start date.
6. Click *Search* and then select the appropriate member in the member list.
7. Complete all required fields and submit the request.

If you're registered for Availity Essentials™ but aren't able to access it, submit the prior authorization request using the *Medication Authorization Request Form*, or *MARF*, that's on the next page. Fax it to the number on the form.

Non-Michigan prescribers

When submitting prior authorization requests, prescribers located outside of Michigan should complete the appropriate steps on the [Getting Started](#) page on ereferrals.bcbsm.com. Look in the *Submit prior authorization requests* section.

If a non-Michigan prescriber is unable to submit a prior authorization request using the instructions on the webpage, submit the request using the *Medication Authorization Request Form*, or *MARF*, that's on the next page. Fax it to the number on the form.

Information about the Medical and Pharmacy Drug PA Portal

To help you learn how to use the Medical and Pharmacy Drug PA Portal, view a recorded demo by going to Blue Cross and BCN's Provider Training site, searching on *drugs* and launching the *Medical and Pharmacy Drug PA Portal Overview*.

For detailed information about accessing the Provider Training site, see the "Online training" section of the [Training Tools](#) page on ereferrals.bcbsm.com.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

Medication Authorization Request Form

Granix® (tbo-filgrastim) J1447, Neupogen® (filgrastim) J1442; Fulphila® (pegfilgrastim-jmdb) Q5108; Fylnetra® (pegfilgrastim-pbbk) Q5130; Neulasta® (pegfilgrastim) J2506; Nivestym® (filgrastim-aafi) Q5110; Nyvepri® (pegfilgrastim-apgf) Q5122; Releuko® (filgrastim-ayow) Q5125; Rolvedon® (eflapregastim-xnsxt) J1449; Stimufend® (pegfilgrastim-fpgk) Q5127; Udenyca® (pegfilgrastim-cbqv) Q5111; Zarxio® (filgrastim-sndz) Q5101; Ziextenzo® (pegfilgrastim-bmez) Q5120, Udenyca® Onbody (pegfilgrastim-cbqv) Q5111, Ryzneuta (Efbemalenograstim alfa) J9361

This form is to be used by participating physicians to obtain coverage for Colony-Stimulating Factors. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION

PHYSICIAN INFORMATION

Name

Name

ID Number

Specialty

D.O.B.

☐ Male ☐ Female

Address

Diagnosis

City /State/Zip

Drug Name

Phone/Fax: P: () - F: () -

Dose and Quantity

NPI

Directions

Contact Person

Date of Service(s)

Contact Person Phone
/ Ext.

STEP 1: DISEASE STATE INFORMATION

1. Initial or Continuation request? ☐ Initial ☐ Continuation Date patient started therapy: _____

2. Please specify the location of administration (e.g. name of facility):

3. Please provide the NPI number for the place of administration: _____

4. Initiation AND Continuation of therapy:

- a. What is the patient's diagnosis? _____
- i. Is the requested drug being used to treat an FDA-approved indication?
☐ Yes ☐ No ☐ Unknown

b. **For Granix, Releuko, or Neupogen:** Please select the preferred colony-stimulating factor(s) the patient has experienced an intolerance, contraindication, or adverse event for the requested indication. Please provide date and type of intolerance patient has had.

- ☐ Nivestym Date: _____ Intolerance: _____
- ☐ Zarxio Date: _____ Intolerance: _____
- ☐ Other; Please specify: _____

c. **For Fulphila, Ziextenzo, Fylnetra, Udenyca, Stimufend, Ryzneuta or Udenyca Onbody:** Please select the preferred colony-stimulating factor(s) the patient has experienced an intolerance, contraindication, or adverse event for the requested indication. Please provide date and type of intolerance patient has had.

- ☐ Udenyca Date: _____ Intolerance: _____
- ☐ Udenyca Onbody Date: _____ Intolerance: _____
- ☐ Nyvepria Date: _____ Intolerance: _____
- ☐ Fulphila Date: _____ Intolerance: _____
- ☐ Other; Please specify: _____

5. **Continuation of therapy** - Please include rationale for continuation of therapy:

Please add any other supporting medical information necessary for our review

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

☐ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name

Physician Signature

Date

Step 2:
Checklist

- ☐ Form Completely Filled Out
- ☐ Attached necessary chart notes

☐ Important laboratory results

Step 3:
Submit

By Fax: BCBSM Specialty Pharmacy Mailbox
1-877-325-5979

By Mail: BCBSM Specialty Pharmacy Program
P.O. Box 312320, Detroit, MI 48231-2320